Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMeagan O'BRIEN, Gary HERMAN, Allen RADIN, Michelle DEVEAUX, Lorah PERLEE, Jamie ORENGO
Estimating the term…
The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.
A method for increasing the time to early asthmatic response (EAR) upon exposure to a cat allergen in a patient having an allergy to the cat allergen, the method comprising administering one or more therapeutically effective doses of at least two allergen-specific monoclonal antibodies or antigen binding fragments thereof to the patient.
A method for increasing the quantity of a cat allergen tolerated by a patient having an allergy to the cat allergen, the method comprising administering one or more therapeutically effective doses of at least two allergen-specific monoclonal antibodies or antigen binding fragments thereof to the patient.
A method for improving lung function and/or for reducing acute bronchoconstriction upon exposure to a cat allergen in a patient having mild asthma and an allergy to the cat allergen, the method comprising administering one or more therapeutically effective doses of at least two allergen-specific monoclonal antibodies or antigen binding fragments thereof to the patient.
Dependencies are inferred from the claim text.